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A B S T R A C T
Background: The percentage of cancer patients diagnosed at an early stage is reported publicly for geo-
graphically-defined populations corresponding to healthcare commissioning organisations in England, and
linked to pay-for-performance targets. Given that stage is incompletely recorded, we investigated the extent to
which this indicator reflects underlying organisational differences rather than differences in stage completeness
and chance variation.
Methods: We used population-based data on patients diagnosed with one of ten cancer sites in 2013 (bladder,
breast, colorectal, endometrial, lung, ovarian, prostate, renal, NHL, and melanoma). We assessed the degree of
bias in CCG (Clinical Commissioning Group) indicators introduced by missing-is-late and complete-case speci-
fications compared with an imputed ‘gold standard’. We estimated the Spearman-Brown (organisation-level)
reliability of the complete-case specification. We assessed probable misclassification rates against current pay-
for-performance targets.
Results: Under the missing-is-late approach, bias in estimated CCG percentage of tumours diagnosed at an early
stage ranged from−2 to−30 percentage points, while bias under the complete-case approach ranged from−2
to +7 percentage points. Using an annual reporting period, indicators based on the least biased complete-case
approach would have poor reliability, misclassifying 27/209 (13%) CCGs against a pay-for-performance target in
current use; only half (53%) of CCGs apparently exceeding the target would be correctly classified in terms of
their underlying performance.
Conclusions: Current public reporting schemes for cancer stage at diagnosis in England should use a complete-
case specification (i.e. the number of staged cases forming the denominator) and be based on three-year re-
porting periods. Early stage indicators for the studied geographies should not be used in pay-for-performance
schemes.
1. Introduction
The percentage of cancer patients diagnosed at an ‘early stage’ (i.e.
TNM stages 1–2) has been routinely reported for National Health
Service commissioning organisations (Clinical Commissioning Groups,
CCGs) since 2014 [1], following recommendations in the 2011 national
cancer strategy for England [2]. Recently, this indicator has been
adopted into a pay-for-performance scheme for CCGs [3]. Typical CCGs
meeting the relevant targets in a given year would receive a financial
incentive of £250,000. The aim of these public reporting and pay-for-
performance schemes is to promote diagnosis of cancer at an earlier
stage and thereby improve outcomes for patients across England. We
further summarise this policy context and the technical aspects of the
indicator in Box 1.
Indicators used for comparing the performance of healthcare orga-
nisations should, among other considerations, be both valid and reli-
able. Valid indicators truly measure the intended construct of interest,
while reliability indicates the precision by which the construct is
measured. The validity of performance indicators based on routinely-
collected healthcare data may be undermined by missing information
[4,5]. Low reliability, where measures are not precise enough to dis-
tinguish organisational performance, is a prevailing concern when
person-level measures are aggregated into organisation-level scores
[6–9]. Frequently, indicators are published and used in pay-for-
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performance schemes without these concerns being examined or ad-
dressed.
The validity and reliability of the early stage indicator for CCGs as
currently specified have not been evaluated. Currently, patients with
cancer with no recorded stage are treated as though they had late stage
cancer, but an alternate specification excluding such patients may be
more appropriate. Furthermore, the annual reporting period may be
either unnecessarily long or too short to allow for reliable estimation of
performance. In this article, we demonstrate how appropriate statistical
techniques may be used to examine the properties of this indicator, and
identify specific improvements to reduce bias and improve its relia-
bility.
2. Materials and methods
2.1. Data sources
We used population-based data (Public Health England National
Cancer Registration and Analysis Service) on TNM stage at diagnosis
and other patient and tumour characteristics of patients diagnosed
during 2013 with 10 common cancers: bladder (ICD10 C67); female
breast (C50); colorectal (C18–C20); endometrial (C54); lung
(C33–C34); ovarian (C56–C574); prostate (C61); and renal (C64) can-
cers; melanoma (C43); and non-Hodgkin lymphoma (C82–C85). The
choice of cancer sites and definition of early stage (TNM stages 1–2)
reflected those included in the Public Health Outcomes Framework and
the CCG Quality Premium; for both, data relating to patients diagnosed
in 2013 was reported in 2014 [1,3,10,11].
2.2. Analysis
2.2.1. Examining bias arising from missing data in indicators of early stage
at diagnosis
In the study year (2013) stage completeness across all 10 cancer
sites was 82%, ranging from 71% to 91% for renal and endometrial
cancer, respectively. We used multiple imputation by chained equations
(MI) to produce a ‘best estimate’ early stage indicator, which we treated
as the gold standard. Separately by cancer site, a binary early stage
indicator for each patient was imputed with logistic regression [12],
using auxiliary information on important patient and tumour char-
acteristics associated with stage at diagnosis including patient age, sex,
tumour grade (partially missing), CCG, and survival time from diag-
nosis [13–16]. The MI indicator for each CCG was estimated as the
mean percentage of tumours diagnosed at early stage over ten imputed
datasets [17]. Appendix A contains further details of the imputation
model.
We judged a priori that indicators based on the MI approach were
not suitable for routine use in public reporting, primarily due to the
need for follow-up periods to have elapsed to obtain survival in-
formation for use in imputation models, as well as the computational
complexity and lack of end-user familiarity with the underlying statis-
tical methods. Instead simpler approaches would be preferable if they
are not associated with a substantial degree of bias. We therefore in-
vestigated the degree of bias in CCG scores using two simpler ap-
proaches for producing early stage indicators. First, the ‘missing-is-late’
indicator, where the percentage of all tumours with recorded early
stage is estimated assuming that those without recorded stage in-
formation are advanced stage tumours. The missing-is-late approach is
currently used to produce early stage indicators [1,3,10]. Second, the
‘complete-case’ indicator, where the percentage of staged tumours di-
agnosed at early stage is estimated based only on tumours with ob-
served stage. We described the degree of bias in either missing-is-late or
complete-case indicators by comparing organisational estimates against
the ‘best estimate’ MI indicator.
2.2.2. Examining the reliability of early stage indicators
The statistical reliability of a measure indicates its reproducibility
(consistency) in repeated measurement and its robustness to random
measurement error. Here we are concerned with organisation-level (or
Spearman-Brown) reliability which represents the extent to which or-
ganisational measures (in our case the measured percentages of cancer
patients diagnosed in early stage) reflect true differences between or-
ganisations, as opposed to random (i.e. chance) variation [7,18–20].
For further details of the calculation of reliability for binary indicators,
see Appendix B.
Mixed effects logistic regression models were used to model varia-
tion in the percentage of tumours diagnosed at early stage estimated
using the complete-case indicator. Our main focus was the composite
(all 10 cancers) indicator for CCGs, but we performed similar analyses
for each individual cancer site (see Appendix B) and for local govern-
ment organisations (local authorities) and general practices. These
models produced an estimate of the organisation-level variance on the
log-odds scale. The estimated variance was used to calculate odds ratios
for diagnosis at early rather than late stage comparing the 75th/25th
and 95th/5th percentiles of the distribution to illustrate the variation
between organisations. Importantly, this was the underlying (true)
variation which can be thought of as that which would be seen with
very large sample sizes in each organisation, such that the influence of
sampling variation would be minimal. This underlying (true) variation
will be less than the variation in observed stage metrics as the latter will
also include a contribution from chance/sampling [19]. The organisa-
tion-level variance on the log-odds scale was also used to calculate the
reliability for each indicator based on the number of cases in the study
year.
In addition to estimating the reliability of the observed data, model
outputs were used to estimate the number of tumours required for each
Box 1
Early stage at diagnosis indicator
In the English National Health Service (NHS), the planning, funding and monitoring of healthcare delivery is the responsibility of
‘healthcare commissioning’ organisations currently known as Clinical Commissioning Groups. These are responsible for geographically-
defined populations. There are about 200 Clinical Commissioning Groups across England, covering an average general population of about
250,000 residents. To support and promote their planning, funding and monitoring function, high level performance indicators for Clinical
Commissioning Groups are published annually, across different disease areas, including cancer. In England, a nationwide population-based
cancer registration system has been in existence since 1971. In recent years, the modernisation of cancer registration systems has enabled
the capturing of information on stage at diagnosis for a high proportion of patients. This has allowed for the introduction of the ‘early
diagnosis’ indicator for Clinical Commissioning Groups studied in our paper. This indicator relates to the stage at diagnosis of 10 different
solid tumour sites, and can be met by a Clinical Commissioning Group if either of the following criteria apply: a) 60% or greater proportion
of all registered cases with relevant tumours are known to have been diagnosed in TNM stages 1 or 2; or b) there has been a 4% or greater
absolute increase within a year in the proportion of all registered cases with relevant tumours known to have been diagnosed in TNM stages
1 or 2.
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organisation to have a reliable estimate of the percentage diagnosed at
an early stage based on reliability thresholds of 0.7 and 0.9. A reliability
of 0.7 or higher is commonly required in public reporting, while a re-
liability of 0.9 may be required for high-stakes reporting, including pay-
for-performance schemes [6,19–21]. Following this we calculated the
number of years of data required for reliable reporting at current
completeness levels.
To illustrate the direct impact of low reliability, we used the esti-
mated distribution of CCG performance in 2013 to evaluate expected
misclassification rates for CCGs on the Quality Premium pay-for-per-
formance thresholds. Estimating the overall CCG misclassification rate
(in respect of both targets combined) was not possible using one year of
data. We therefore performed two similar simulation processes, one for
investigating the 60% criterion and one for the ≥4% change criterion
(Appendix D). This proceeded as follows. We started with a list of 209
CCGs and the number of staged tumours (Ni) in 2013 for each CCG. We
simulated plausible values of the true performance of each CCG, Pi,
using the intercept and random effect from our multi-level model, and
mapping back from the logistic to the probability scale. We used the
binomial distribution with probability of success Pi and number of trials
Ni to generate plausible observed performances for each CCG, given the
simulated underlying performance and actual number of staged tu-
mours. For the ≥4% change criterion we simulated two years of data
for each CCG with a true, uniform change in performance between the
two years, repeated for true changes between−4% and +12%, in steps
of 0.1%. We repeated each simulation 10,000 times, examining the
sensitivity, specificity, and positive and negative predictive values of
both the 60% and≥4% change criteria. All analyses were carried out in
Stata 13 [22].
3. Results
Of 208,112 diagnoses of relevant tumours in 2013, 98,218 (47%)
were diagnosed in early stage (1–2), 71,809 (35%) were diagnosed in
stages 3–4, and 38,085 (18%) had no recorded stage information (Fig.
A1).
3.1. Bias arising from missing data in indicators of early stage at diagnosis
Comparing with the ‘best estimate’ indicator based on multiply
imputed data for CCGs (median 55% early stage, range 45%–66%), the
missing-is-late indicator underestimated true performance (median
48%, range 25%–62%), while the complete-case indicator over-
estimated true performance (median 57%, range 48%–70%).
There was little association between CCG early stage percentages
estimated using the indicator based on multiply imputed data and CCG
percentages of tumours with missing stage (Fig. 1 panel A). In contrast,
when using the missing-is-late specification, we observed a very strong
negative relationship between early stage and missing stage percen-
tages (panel B). The complete-case specification did not show a clear
association of these two measures (panel C).
Fig. 2 shows the bias associated with the amount of missing stage
information compared with the ‘best estimate’ MI indicator (i.e. where
bias is the difference between the ‘best estimate’ MI indicator and the
indicator of interest). Bias in the missing-is-late specification increased
in magnitude rapidly as the percentage of tumours with missing stage
information increased; median bias across all CCGs was −6% (range
−30% to −2%). Using a complete case specification typically pro-
duced less biased estimates than the missing-is-late approach across all
CCGs, irrespectively of the degree of data completeness. There was a
slight positive association between the degree of bias and the percen-
tage of patients with missing stage among CCGs with<20% missing
stage data, and no apparent association among CCGs with> 20%
missing stage data. Median bias in the complete-case specification
across all CCGs was +2% (range−2% to +7%). Importantly, between-
CCG variation in bias due to missing data under the missing-is-late
specification (observed range of bias: 28%) was larger than observed
variation in early stage on the ‘best estimate’ (observed range of per-
formance: 21%), while this was not the case for the complete-case in-
dicator (observed range of bias: 9%).
3.2. Reliability of the complete-case indicator
The median reliability of the early stage indicator for CCGs was 0.66
(Table 1), despite strong evidence of variation between CCGs
(p < 0.0001) and moderate sample sizes for each CCG (median 691
staged tumours). This is below levels of reliability required for use in
public reporting or pay-for-performance schemes. The aggregation of
three years of data would suffice to produce indicators suitable for
public reporting (λ≥ 0.7) for 90% of CCGs. Indicators for 90% of CCGs
with sufficient reliability for use in pay-for-performance schemes
(λ≥ 0.9) would require aggregation of nine years of data. Reliability
estimates for individual sites are given in Table C1. For breast and lung
cancer, indicators based on three and four years of incident cases re-
spectively would allow for adequate reliability (λ≥ 0.7) for about 70%
of all CCGs, respectively. For other cancer sites, eight (renal cancer) to
35 (endometrial cancer) years would be required. Results for local
authorities were similar, while general practice indicators had very low
reliability (Table C2).
3.3. Probable misclassification on CCG Quality Premium targets for
reporting periods of varying length
Considering the CCG Quality Premium criterion providing financial
incentives to CCGs which have 60% of tumours diagnosed at stage 1 or
2 in a single year, based on our simulation (which assumes the com-
plete-case indicator is used), we would expect 40 of the 209 CCGs to
appear to meet this 60% target, of which only 21 would have an un-
derlying or long-run performance of 60% or higher, giving a positive
predictive value of 53% (Fig. 3). We would expect 29 CCGs to have
underlying performance above the 60% target, of which one quarter
(eight of 29) would appear to miss the target, giving a sensitivity of
74%. Aggregating multiple years of data reduces expected mis-
classification rates. Using 2.5 (9) years of data, giving reliability of 0.7
(0.9) for more than 90% of CCGs, increases the expected number of true
positives to 23 (25) and reduces the expected number of false positives
to 11 (5) (Table C3).
For the 4% year-on-year increase criterion of the CCG Quality
Premium, misclassification rates depend on the size of underlying
changes in performance expected in the long-term for individual CCGs
as well as CCG size. If the CCGs' underlying performance did not
change, then with very large sample sizes we would not expect to see
any CCGs meet this target. However, based on the actual sample sizes
for one year of data we would expect 8% of CCGs to be misclassified as
meeting the target if the underlying performance did not change for any
CCG (Fig. 4). Furthermore, for a CCG to have an 80% chance of meeting
the 4% improvement target they would have to improve their under-
lying performance such that they increased the percentage of cases
diagnosed at early stage by 6.2% (Fig. 4).
4. Discussion
The current specification of the early stage indicator for English
commissioning organisations is biased due to organisational variation
in stage completeness. For the period we examine, the degree of bias is
so large that it dominates the variability in this indicator. An alternative
specification of the indicator based only on tumours with recorded
stage is substantially less biased. Nonetheless, such complete-case in-
dicators will not be reliable when based on one year of data, and will be
associated with a high degree of random misclassification if used in
pay-for-performance schemes. Complete-case indicators will be suitable
for public reporting if based on three-year reporting periods. Timely
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Fig. 1. Observed early-stage percentage calculated using: A. the ‘best es-
timate’ multiple imputation approach; B. the missing-is-late approach; and
C. the complete-case approach, plotted against the percentage of tumours
with no recorded stage information, CCGs, England 2013.
Fig. 2. Bias in scores calculated using the complete-case and
missing-is-late approaches when compared with the ‘best es-
timate’ MI indicator, plotted against the percentage of tu-
mours with no recorded stage information, CCGs, England
2013.
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early stage indicators suitable for pay-for-performance use are not
feasible.
There are no previously published evaluations of the bias or relia-
bility of indicators of cancer stage at diagnosis. Many studies have
evaluated the reliability of other performance indicators in healthcare
for physicians [7,9], hospitals [23,24], and general practices [8,21] –
including for several diagnostic activity indicators reported in the
Cancer Services Public Health Profiles [19]. Bias due to missing data is
also a common problem for measures based on routinely-collected data,
and multiple imputation in particular is commonly used to correct this
in cancer registry data [4,25,26].
The key strength of our study is that we use the same English cancer
registry data as the early stage indicator, ensuring our results are di-
rectly relevant to the current public reporting and pay-for-performance
schemes in England. The main weakness is the lack of an objective gold
standard for assessing bias in the indicator. Our estimates of bias under
different specifications of the indicator are based on comparisons with
complete data produced using multiple imputation, as by definition we
do not know the stage of tumours with no recorded stage. This ap-
proach could itself be biased if the ‘missing at random’ assumption does
not hold, but this is mitigated by the inclusion of important auxiliary
information in the imputation process [15,16,25].
As we had no data on successive years, we only estimated true
misclassification rates against the 60% early stage target, but as we
have shown, CCGs may be additionally misclassified when considering
the 4% early stage improvement criterion. The degree of mis-
classification we report represents an under-estimate.
Among the 10 cancer sites included in the current indicators, some
have higher than average proportion of late stage disease (e.g. lung
cancer) whereas the opposite is true for other sites (e.g. breast cancer).
The indicator does not take into account between-CCG variation in site-
specific incidence or in patient demographics, and this may reduce the
validity of the current indicator for comparing CCG performance
[27,28]. Adjusting for case-mix factors would be expected to reduce
variation between organisations, and so a potential case-mix adjusted
indicator might be more valid but less reliable. Future studies should
establish the degree by which case-mix drives apparent organisational
attainment and potential implications for public reporting conventions.
Continuing improvements in stage completeness in English cancer
registry data will reduce the size and the variation of bias in the
missing-is-late approach. However, bias due to missing stage informa-
tion under this approach will remain a major problem until all CCGs
have very similar stage completeness rates. In our study year the al-
ternative complete-case approach has less bias than the current missing-
is-late approach even for CCGs with very high stage completeness, and
so would be expected to remain the best option as stage completeness
continues to improve.
Aggregating 3 years of data will produce a reliable early stage in-
dicator, suitable for use in public reporting, and we endorse this ap-
proach. Pay-for-performance schemes for Clinical Commissioning
Table 1
Number of CCGs, staged tumours per CCG, odds ratios over estimated underlying dis-
tribution of CCG performance, quartiles of the reliability of the complete-case early stage
indicator, and the number of tumours and associated aggregated years of data for 50%,
70%, 90% and 100% of CCGs to have reliability of 0.7 or higher or of 0.9 or higher.
CCGs 209
Number of staged tumours per CCG Minimum 125
25th percentile 479
Median 691
75th percentile 943
Maximum 3575
Odds ratio over CCG distribution* 75th/25th percentiles 1.16
95th/5th percentiles 1.43
Reliability Minimum 0.26
25th percentile 0.58
Median 0.66
75th percentile 0.73
Maximum 0.91
Number of tumours per CCG required for
reliability 0.7
50% of units 803
70% of units 812
90% of units 833
All units 926
Data years required for reliability 0.7 50% of units 1.2
70% of units 1.5
90% of units 2.3
All units 6.6
Number of tumours per CCG required for
reliability 0.9
50% of units 3095
70% of units 3132
90% of units 3210
All units 3570
Data years required for reliability 0.9 50% of units 4.5
70% of units 5.6
90% of units 8.7
All units 25.3
* p < 0.0001. Odds ratio calculated directly from the estimated variance of the
random intercept from the mixed-effects logistic regression ( =σˆ2 0.012) using the ap-
propriate centiles of the standard normal distribution. The 75th/25th percentile odds
ratio is calculated as ×e(1.35 0.012 ) and the 95th/5th percentile odds ratio is calculated as
×e(3.29 0.012 ).
Fig. 3. Estimated number of true positives, false
positives, true negatives and false negatives, with
associated sensitivity, specificity, positive and nega-
tive predictive values (95% confidence intervals), for
the 60% early stage target given performance similar
to 2013 and tumours counts as in 2013.
M.E. Barclay et al. Cancer Epidemiology 52 (2018) 28–42
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Groups should not use the early stage indicator, as sufficiently reliable
indicators require more than eight aggregate years of data which
greatly limits potential uses. The resulting high levels of misclassifica-
tion on the indicator when based on a single year mean that many CCGs
will receive financial rewards despite their underlying performance
being below the pay-for-performance threshold. The opposite is also
true, i.e. some CCGs should be rewarded but will not be.
Appropriate process indicators could give more accurate, reliable,
and timely information about local diagnostic performance for cancer
[29,30], where there are clear links between processes and improved
stage at diagnosis, survival, or quality of life. Screening coverage, for
example, is a useful measure for breast, colorectal and cervical cancers
[31,32]. Other examples might include organisational measures of use
of endoscopies or urgent referrals for suspected cancer (otherwise
known as ‘two-week-wait’ referrals), as they are associated with clinical
outcomes [33,34]. More generally, there is a need for research to
identify diagnostic process indicators which are truly linked to better
outcomes for cancer patients, and to identify the organisations best-
placed to improve local and national performance.
The development of indicators of cancer diagnosis must involve the
evaluation and correction of issues of bias and low reliability. The
methods we have highlighted here allow for investigation of these
problems, and should form part of the process for the development of
such indicators before their introduction into practice. Organisations
should not be ranked on severely biased quality measures, and financial
incentives should only be linked to highly reliable indicators. Cancer
stage indicators should not form part of pay-for-performance schemes
for CCGs, and public reporting of the early stage indicator should use
three-year reporting periods and be calculated as the percentage of
staged tumours diagnosed at an early stage.
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Appendix A. Details of multiple imputation of stage for patients with tumours with no recorded stage information
Stage data were 82% complete overall, with at least 70% completeness for each cancer site. However, stage completeness and the distribution of
stage at diagnosis where known varied substantially by site (Fig. A1), and stage completeness also varied substantially by CCG (Fig. A2).
Multiple imputation is a recommended method for handling missing stage information in cancer registry data (Table A1). We created a binary
stage variable being ‘early’ (TNM stages 1 or 2) or ‘late’ (TNM stages 3 or 4) stage. Imputation was performed separately for each cancer site, splitting
colorectal cancer into colon and rectal cancer.
We used logistic regression to impute the binary indicator of early stage at diagnosis on:
• CCG of patient at diagnosis
• Region of residence of patient at diagnosis
• Sex of patient
• Interaction between sex and region
• Age group of patient at diagnosis (30–39, then five-year age groups, then 90–99, except for prostate and bladder cancer where the youngest age
group was 30–44 due to smaller numbers in this age range)
• Interaction between age group and region
• Deprivation group, fifth of the income domain of IMD 2010
• Interaction between deprivation group and region
• Ethnicity of patient (white or non-white)
Fig. 4. Expected percentage of CCGs with observed increases in the early
stage percentage of 4 percentage points or more, given uniform national
changes of between −4 and +12 percentage points. For example, for a
typical CCG to have an 80% chance of being classified as achieving a 4%-
point increase (blue dashed line), it would need to have an underlying
increase of 6.2%-points. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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• Interaction between ethnicity and region
• Nelson-Aalen estimate of cumulative hazard, censored at 365 days after diagnosis
• Indicator of death within 365 days after diagnosis
• Indicator of death within 30 days after diagnosis (not included in imputation of stage for endometrial cancer or melanoma)
• Basis of diagnosis (non-microscopic/microscopic, not included in imputation of stage for endometrial cancer or melanoma)
• Screening detection status (for breast, colon and rectal cancer only)
• Tumour grade (1/2/3/4, not considered for melanoma)
Fig. A1. Percentage of tumours by stage at diagnosis, England 2013.
Fig. A2. Percentage of staged tumours which were stage 1 or 2 against percentage of all tumours which were staged, by CCG, England 2013, with LOESS line.
M.E. Barclay et al. Cancer Epidemiology 52 (2018) 28–42
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We only included patients aged 30–99 at diagnosis. We felt that predictors of stage at diagnosis for patients outside this age range may not reflect
those of more typical patients. There were few patients either aged 29 and under (1591 of 208,141, 0.8%) or 100 and older (104 of 208,141, 0.05%),
so separate imputation was not feasible.
Screening detection status was applicable for breast, colon and rectal cancers. For melanoma and endometrial cancer, early mortality and non-
microscopic diagnosis were both extremely rare and the inclusion of such indicators led to problems with model convergence. For melanoma, tumour
grade is both less clinically relevant and had low completeness..
All variables used in imputation models were complete, except for tumour grade. For cancer sites other than melanoma, we used predictive mean
matching to impute tumour grade based on the (possibly imputed) binary indicator of early stage at diagnosis and on the other variables and
interactions used in imputing stage.
Thus for melanoma we used multiple imputation by logistic regression, while for other sites we used multiple imputation by chained equations.
We used ten iterations of the chain as burn-in, having previously checked graphically that doing so led to convergence.
Appendix B. Organisation-level reliability for binary indicators
The statistical reliability of a measure generally indicates its reproducibility (consistency) in repeated measurement and its robustness to random
measurement error. Here we are concerned with organisation-level reliability, also termed unit-level reliability where units could be commissioners,
providers, or geographical areas. In the context of our study, organisation-level (or Spearman-Brown) reliability represents the extent to which
measured percentages of cancer patients diagnosed in early stage reflect true differences between organisations, as opposed to random (i.e. chance)
variation. Alternatively, the Spearman-Brown reliability is the proportion of the observed organisational variation not due to chance.
Poor reliability often arises when the typical number of cases per organisation (in a given reporting period) is small. The problem is further
exacerbated when small sample sizes are combined with limited variation between organisations. Reliable indicators can help to classify organi-
sational performance and thus enable accurate targeting of improvement efforts and rewards. Conversely, using unreliable indicators can lead to
harm through wasting of scarce improvement resources and related opportunity costs. Further, misclassified ‘poorly performing’ organisations may
sustain unfair reputational or financial loss [6,9].
Reliability takes a value between 0 and 1, with higher values denoting more reliable indicators. A reliability of 0.5 indicates that half of the
observed variance is due to chance. A reliability of 0.7 is often required for public reporting of indicators, while a reliability of 0.9 may be required
for pay-for-performance use [6,20,21]. Organisation-level reliability λi for organisation i is defined as
=
+
λ between-organisation variance
between-organisation variance
i
n
within-organisation variance
i
where ni = achieved sample size for organisation i.
For continuous indicators, this calculation is straightforward [6]. For binary indicators, the within-organisation variance will depend directly on
the level of achievement at each individual organisation, according to the binomial distribution [18,20]. It is important to note that as reliability
depends on both the organisational sample size and organisational achievement it is specific to each organisation rather than to the indicator as a
whole.
We used mixed effects logistic regression models to estimate the organisation-level variance on the log-odds scale (ˆ σ2). Reliability is then given
by
=
+
× − ×
ˆˆ ˆ ˆ
λ σ
σ
i
π π n
2
2 1
(1 )i i i
whereˆπi is the observed performance of organisation i on the indicator as a proportion [18]. From this formula it can be seen that higher reliabilitycan be achieved by increasing the between-unit variation or by increasing sample sizes. Additionally, for binary indicators, higher reliability is
achieved with performance closer to 50%.
Appendix C. Reliability of early stage indicators for the composite indicator for CCGs, local authorities and general practices, with years
of data required for indicators suitable for public reporting and pay-for-performance use and associated expected misclassification rates
Table C1
Number of organisations, staged tumours per organisation, odds ratios over estimated underlying distribution of organisational performance, quartiles of the reliability of the complete-
case early stage indicator, and the number of tumours and associated aggregated years of data for 50%, 70%, 90% and 100% of organisations to have reliability of 0.7 or higher or of 0.9
or higher, for CCGs, local authorities and general practices.
CCG LA GP
Units with staged tumours 209 326 8075
Staged tumours per unit Minimum 125 12 1
25th percentile 479 311 9
Median 691 427 17
75th percentile 943 634 30
Maximum 3575 2992 150
Odds ratio over unit distribution* 75th/25th
percentiles
1.16 1.18 1.29
95th/5th
percentiles
1.43 1.49 1.85
(continued on next page)
M.E. Barclay et al. Cancer Epidemiology 52 (2018) 28–42
36
Table C2
National number of diagnoses and median reliability of complete-case composite and site-specific early stage indicators for general practices, CCGs and local authorities, with number of
years of data at current completeness levels required for reliable indicators for 70% of organisations.
Cancer site Tumours Median reliability Years of data required for reliable indicators (λ≥ 0.7) for 70% of organisations
Total Staged Stage 1–2 GP CCG LA GP CCG LA
All ten sites combined 208,141 172,001 98,780 0.12 0.66 0.61 30.2 1.5 2.0
Breast 44,558 37,465 31,635 0.08 0.59 0.42 28.7 2.3 4.8
Prostate 39,934 32,859 19,422 0.05 0.71 0.62 75.3 1.3 1.9
Lung 35,972 31,234 7307 0.02 0.44 0.32 142.0 4.0 7.0
Colorectal 33,477 27,719 12,398 0.04 0.26 0.15 92.0 8.7 17.3
Melanoma 12,245 10,520 9591 0.10 0.26 0.19 34.0 9.7 19.2
NHL 11,222 8080 2916 0.33 0.24 7.0 10.8
Endometrial 7232 6615 5405 0.10 0.06 30.6 50.1
Bladder 8669 6505 4835 0.25 0.14 10.3 22.7
Renal 8368 5970 3202 0.28 0.21 8.1 13.4
Ovarian 6464 5034 2069 0.14 0.14 20.7 21.6
Table C1 (continued)
CCG LA GP
Reliability Minimum 0.26 0.04 0.01
25th percentile 0.58 0.53 0.06
Median 0.66 0.61 0.12
75th percentile 0.73 0.70 0.20
Maximum 0.91 0.92 0.56
Tumours required for reliability
0.7
50% of units 803 641 280
70% of units 812 652 302
90% of units 833 668 358
All units 926 784 1546
Data years required for reliability
0.7
50% of units 1.2 1.5 17.1
70% of units 1.5 2.0 30.2
90% of units 2.3 2.7 89.5
All units 6.6 53.7 269.0
Tumours required for reliability
0.9
50% of units 3095 2470 1078
70% of units 3132 2514 1165
90% of units 3210 2575 1380
All units 3570 3022 5963
Data years required for reliability
0.9
50% of units 4.5 5.8 65.8
70% of units 5.6 7.5 116.4
90% of units 8.7 10.5 345.0
All units 25.3 206.8 1,035.0
* p < 0.0001 across CCGs, LAs and GPs.
Table C3
Estimated number of true positives, false positives, true negatives and false negatives, with associated sensitivity, specificity, positive predictive value and negative predictive values (95%
confidence intervals), for the 60% early stage target given performance similar to 2013 and tumours counts as in 2013 for reporting periods of 1, 2.5 and 9 years.
Reporting period 1 year 2.5 years 9 years
Expected value (95% CI) Expected value (95% CI) Expected value (95% CI)
True positives 21 (13, 50) 23 (15, 32) 25 (16, 35)
False positives 19 (11, 28) 11 (6, 18) 5 (1, 10)
True negatives 161 (149, 172) 169 (157, 179) 175 (164, 185)
False negatives 8 (3, 14) 6 (2, 11) 4 (1, 8)
Sensitivity 0.73 (0.56, 0.89) 0.80 (0.64, 0.93) 0.88 (0.73, 0.97)
Specificity 0.89 (0.85, 0.94) 0.94 (0.90, 0.97) 0.97 (0.94, 0.99)
Positive predictive value 0.52 (0.37, 0.68) 0.67 (0.50, 0.82) 0.83 (0.68, 0.95)
Negative predictive value 0.95 (0.92, 0.98) 0.97 (0.94, 0.99) 0.68 (0.96, 0.99)
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Appendix D. Stata code for estimating expected misclassification rates on the 60% early stage and 4% increase in early stage criteria
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